References
- Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020. DOI:https://doi.org/10.4193/Rhin20.600
- Stevens WW, Lee RJ, Schleimer RP, et al. Chronic rhinosinusitis pathogenesis. J Allergy Clin Immunol. 2015;136(6):1442–1453.
- Rudmik L, Smith TL, Mace JC, et al. Productivity costs decrease after endoscopic sinus surgery for refractory chronic rhinosinusitis. Laryngoscope. 2016. DOI:https://doi.org/10.1002/lary.25656
- Slovick A, Cornet M, Surda P, et al. Chronic rhinosinusitis: new understanding of specific and general quality of life scores. Rhinology. 2016;54(4):289–291.
- Huang A, Govindaraj S. Topical therapy in the management of chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg. 2013;21(1):31–38.
- Chong LY, Head K, Hopkins C, et al. Different types of intranasal steroids for chronic rhinosinusitis. Cochrane Database Syst Rev. 2021;(3).:CD013513.
- Scadding GK. Optimal management of allergic rhinitis. Arch Dis Child. 2015. DOI:https://doi.org/10.1136/archdischild-2014-306300
- Vlckova I, Navrátil P, Kaňa R, et al. Effective treatment of mild-to-moderate nasal polyposis with fluticasone delivered by a novel device. Rhinology. 2009. DOI:https://doi.org/10.4193/Rhin09.024
- Leopold DA, Elkayam D, Messina JC, et al. NAVIGATE II: randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis. J Allergy Clin Immunol. 2019. DOI:https://doi.org/10.1016/j.jaci.2018.06.010
- Jankowski R, Schrewelius C, Bonfils P, et al. Efficacy and tolerability of budesonide aqueous nasal spray treatment in patients with nasal polyps. Arch Otolaryngol - Head Neck Surg. 2001. DOI:https://doi.org/10.1001/archotol.127.4.447.
- Keith P, Nieminen J, Hollingworth K, et al. Efficacy and tolerability of fluticasone propionate nasal drops 400 μg once daily compared with placebo for the treatment of bilateral polyposis in adults. Clin Exp Allergy. 2000. DOI:https://doi.org/10.1046/j.1365-2222.2000.00932.x
- Holmberg K, Juliusson S, Balder B, et al. Fluticasone propionate aqueous nasal spray in the treatment of nasal polyposis. Ann Allergy, Asthma Immunol. 1997. DOI:https://doi.org/10.1016/S1081-1206(10)63180-8
- Wu EL, Harris WC, Babcock CM, et al. Epistaxis risk associated with intranasal corticosteroid sprays: a systematic review and meta-analysis. Otolaryngol - Head Neck Surg (United States). 2019;161(1):18–27.
- Skoner DP, Rachelefsky GS, Meltzer EO, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics. 2000. DOI:https://doi.org/10.1542/peds.105.2.e23.
- Sheth K. Evaluating the safety of intranasal steroids in the treatment of allergic rhinitis. Allergy, Asthma Clin Immunol. 2008. DOI:https://doi.org/10.1186/1710-1492-4-3-125
- Derby L, Maier WC. Risk of cataract among users of intranasal corticosteroids. J Allergy Clin Immunol. 2000. DOI:https://doi.org/10.1067/mai.2000.106044
- Valenzuela CV, Liu JC, Vila PM, et al. Intranasal corticosteroids do not lead to ocular changes: a systematic review and meta-analysis. Laryngoscope. 2019;129(1):6–12.
- Lam K, Tan BK, Lavin JM, et al. Comparison of nasal sprays and irrigations in the delivery of topical agents to the olfactory mucosa. Laryngoscope. 2013. DOI:https://doi.org/10.1002/lary.24239
- Stokken JK. Saline irrigation and topical nasal steroids. JAMA Otolaryngol - Head Neck Surg. 2019;145(9):880.
- Harvey RJ, Goddard JC, Wise SK, et al. Effects of endoscopic sinus surgery and delivery device on cadaver sinus irrigation. Otolaryngol - Head Neck Surg. 2008. DOI:https://doi.org/10.1016/j.otohns.2008.04.020
- Jang DW, Lachanas VA, Segel J, et al. Budesonide nasal irrigations in the postoperative management of chronic rhinosinusitis. Int Forum Allergy Rhinol. 2013. DOI:https://doi.org/10.1002/alr.21189
- Steinke JW, Payne SC, Tessier ME, et al. Pilot study of budesonide inhalant suspension irrigations for chronic eosinophilic sinusitis. J Allergy Clin Immunol. 2009;124(6):1352–1354.e7.
- Snidvongs K, Pratt E, Chin D, et al. Corticosteroid nasal irrigations after endoscopic sinus surgery in the management of chronic rhinosinusitis. Int Forum Allergy Rhinol. 2012. DOI:https://doi.org/10.1002/alr.21047
- Smith KA, French G, Mechor B, et al. Safety of long-term high-volume sinonasal budesonide irrigations for chronic rhinosinusitis. Int Forum Allergy Rhinol. 2016. DOI:https://doi.org/10.1002/alr.21700
- Soudry E, Wang J, Vaezeafshar R, et al. Safety analysis of long-term budesonide nasal irrigations in patients with chronic rhinosinusitis post endoscopic sinus surgery. Int Forum Allergy Rhinol. 2016. DOI:https://doi.org/10.1002/alr.21724
- Macias-Valle L, Psaltis AJ, Scholarly A. Review of the safety and efficacy of intranasal corticosteroids preparations in the treatment of chronic rhinosinusitis. Ear, Nose Throat J. 2020;014556132096772. DOI:https://doi.org/10.1177/0145561320967727
- Dahlström K, Thorsson L, Larsson P, et al. Systemic availability and lung deposition of budesonide via three different nebulizers in adults. Ann Allergy, Asthma Immunol. 2003. DOI:https://doi.org/10.1016/S1081-1206(10)62146-1
- Wang C, Lou H, Wang X, et al. Effect of budesonide transnasal nebulization in patients with eosinophilic chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2015. DOI:https://doi.org/10.1016/j.jaci.2014.10.018.
- Thamboo A, Manji J, Szeitz A, et al. The safety and efficacy of short-term budesonide delivered via mucosal atomization device for chronic rhinosinusitis without nasal polyposis. Int Forum Allergy Rhinol. 2014. DOI:https://doi.org/10.1002/alr.21280.
- Manji J, Singh G, Okpaleke C, et al. Safety of long-term intranasal budesonide delivered via the mucosal atomization device for chronic rhinosinusitis. Int Forum Allergy Rhinol. 2017. DOI:https://doi.org/10.1002/alr.21910.
- Djupesland PG, Skretting A. Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump. J Aerosol Med Pulm Drug Deliv. 2012. DOI:https://doi.org/10.1089/jamp.2011.0924
- P.G. D. Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review. Drug Deliv Transl Res. 2013;3:42-62.
- Palmer JN, Jacobson KW, Messina JC, et al. EXHANCE-12: 1-year study of the exhalation delivery system with fluticasone (EDS-FLU) in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2018. DOI:https://doi.org/10.1002/alr.22141
- Sher MR, Steven GC, Romett JL, et al. EXHANCE-3: a cohort study of the exhalation delivery system with fluticasone for chronic sinusitis with or without nasal polyps. Rhinology. 2020. DOI:https://doi.org/10.4193/Rhin19.124.
- Adriaensen GFJPM, Lim KH, Fokkens WJ. Safety and efficacy of a bioabsorbable fluticasone propionate–eluting sinus dressing in postoperative management of endoscopic sinus surgery: a randomized clinical trial. Int Forum Allergy Rhinol. 2017. DOI:https://doi.org/10.1002/alr.21963
- Marple BF, Smith TL, Han JK, et al. Advance II: a Prospective, randomized study assessing safety and efficacy of bioabsorbable steroid-releasing sinus implants. Otolaryngol - Head Neck Surg (United States). 2012. DOI:https://doi.org/10.1177/0194599811435968.
- Han JK, Forwith KD, Smith TL, et al. RESOLVE: a randomized, controlled, blinded study of bioabsorbable steroid-eluting sinus implants for in-office treatment of recurrent sinonasal polyposis. Int Forum Allergy Rhinol. 2014. DOI:https://doi.org/10.1002/alr.21426.
- Murr AH, Smith TL, Hwang PH, et al. Safety and efficacy of a novel bioabsorbable, steroid-eluting sinus stent. Int Forum Allergy Rhinol. 2011. DOI:https://doi.org/10.1002/alr.20020.
- Rudmik L, Soler ZM, Hopkins C, et al. Defining appropriateness criteria for endoscopic sinus surgery during management of uncomplicated adult chronic rhinosinusitis: a RAND/UCLA appropriateness study. Int Forum Allergy Rhinol. 2016. DOI:https://doi.org/10.1002/alr.21769.
- Santiago T, Da Silva JAP. Safety of low- to medium-dose glucocorticoid treatment in rheumatoid arthritis: myths and reality over the years. Ann N Y Acad Sci. 2014. DOI:https://doi.org/10.1111/nyas.12428
- Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009. DOI:https://doi.org/10.1136/ard.2008.092163.
- Jap DS, Jacobs JWG, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65:285-293.
- Head K, Chong LY, Hopkins C, et al. Short-course oral steroids alone for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016 Apr 26;CD011991.
- Head K, Chong LY, Hopkins C, et al. Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016 Apr 26;CD0011992.
- Alobid I, Benítez P, Cardelús S, et al. Oral plus nasal corticosteroids improve smell, nasal congestion, and inflammation in sino-nasal polyposis. Laryngoscope. 2014. DOI:https://doi.org/10.1002/lary.24330.
- Alobid I, Benitez P, Pujols L, et al. Severe nasal polyposis and its impact on quality of life. The effect of a short course of oral steroids followed by long-term intranasal steroid treatment. Rhinology. 2006;44:8-13.
- Ecevit MC, Erdag TK, Dogan E, et al. Effect of steroids for nasal polyposis surgery: a placebo-controlled, randomized, double-blind study. Laryngoscope. 2015. DOI:https://doi.org/10.1002/lary.25352
- Hissaria P, Smith W, Wormald PJ, et al. Short course of systemic corticosteroids in sinonasal polyposis: a double-blind, randomized, placebo-controlled trial with evaluation of outcome measures. J Allergy Clin Immunol. 2006. DOI:https://doi.org/10.1016/j.jaci.2006.03.012.
- Kapucu B, Cekin E, Erkul BE, et al. The effects of systemic, topical, and intralesional steroid treatments on apoptosis level of nasal polyps. Otolaryngol - Head Neck Surg (United States). 2012. DOI:https://doi.org/10.1177/0194599812446678
- Kirtsreesakul V, Wongsritrang K, Ruttanaphol S. Clinical efficacy of a short course of systemic steroids in nasal polyposis. Rhinology. 2011. DOI:https://doi.org/10.4193/Rhino11.140
- Vaidyanathan S, Barnes M, Williamson P, et al. Treatment of chronic rhinosinusitis with nasal polyposis with oral steroids followed by topical steroids: a randomized trial. Ann Intern Med. 2011. DOI:https://doi.org/10.7326/0003-4819-154-5-201103010-00003
- Van Zele T, Gevaert P, Holtappels G, et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin Immunol. 2010. DOI:https://doi.org/10.1016/j.jaci.2010.02.020.
- Ozturk F, Bakirtas A, Ileri F, et al. Efficacy and tolerability of systemic methylprednisolone in children and adolescents with chronic rhinosinusitis: a double-blind, placebo-controlled randomized trial. J Allergy Clin Immunol. 2011. DOI:https://doi.org/10.1016/j.jaci.2011.04.045
- Bülbül T, Ög B, Güçlü O, et al. Effect of glucocorticoids on nasal polyposis, with detection of inflammatory response by measurement of nitric oxide levels in nasal polyp tissue. J Laryngol Otol. 2013. DOI:https://doi.org/10.1017/S002221511300073X
- Laursen LC, Faurschou P, Pals H, et al. Intramuscular betamethasone dipropionate vs. oral prednisolone in hay fever patients. Allergy. 1987. DOI:https://doi.org/10.1111/j.1398-9995.1987.tb02194.x
- Bonfils P, Halimi P, Malinvaud D. Adrenal suppression and osteoporosis after treatment of nasal polyposis. Acta Otolaryngol. 2006. DOI:https://doi.org/10.1080/00016480600672667
- Hernández-Díaz S, García Rodríguez LA. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol. 2001. DOI:https://doi.org/10.1093/aje/153.11.1089
- Venekamp RP, Bonten MJM, Rovers MM, et al. Systemic corticosteroid monotherapy for clinically diagnosed acute rhinosinusitis: a randomized controlled trial. CMAJ. 2012. DOI:https://doi.org/10.1503/cmaj.120430
- Brown ES, Suppes T, Khan DA, et al. Mood changes during prednisone bursts in outpatients with asthma. J Clin Psychopharmacol. 2002. DOI:https://doi.org/10.1097/00004714-200202000-00009
- Naber D, Sand P, Heigl B. Psychopathological and neuropsychological effects of 8-days’ corticosteroid treatment. A prospective study. Psychoneuroendocrinology. 1996. DOI:https://doi.org/10.1016/0306-4530(95)00031-3
- Aasbjerg K, Torp-Pedersen C, Vaag A, et al. Treating allergic rhinitis with depot-steroid injections increase risk of osteoporosis and diabetes. Respir Med. 2013. DOI:https://doi.org/10.1016/j.rmed.2013.09.007
- Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193–204.
- Rice JB, White AG, Scarpati LM, et al. Long-term Systemic Corticosteroid Exposure: a Systematic Literature Review. Clin Ther. 2017;39(11):2216–2229.
- Hox V, Lourijsen E, Jordens A, et al. Benefits and harm of systemic steroids for short- And long-term use in rhinitis and rhinosinusitis: an EAACI position paper. Clin Transl Allergy. 2020;10.
- Rajasekaran K, Seth R, Abelson A, et al. Prevalence of metabolic bone disease among chronic rhinosinusitis patients treated with oral glucocorticoids. Am J Rhinol Allergy. 2010. DOI:https://doi.org/10.2500/ajra.2010.24.3445
- Kanis JA. Osteoporosis III: diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359(9321):1929–1936.
- Winblad L, Larsen CG, Håkansson K, et al. The risk of osteoporosis in oral steroid treatment for nasal polyposis: a systematic review. Rhinology. 2017;55(3):195–201.
- Matsumoto H, Ishihara K, Hasegawa T, et al. Effects of inhaled corticosteroid and short courses of oral corticosteroids on bone mineral density in asthmatic patients: a 4-year longitudinal study. Chest. 2001. DOI:https://doi.org/10.1378/chest.120.5.1468
- Stuck AE, Minder CE, Frey FJ. Risk of Infectious Complications in Patients Taking Glucocorticosteroids. Rev Infect Dis. 1989. DOI:https://doi.org/10.1093/clinids/11.6.954
- Aljebab F, Choonara I, Conroy S. Systematic review of the toxicity of short-course oral corticosteroids in children. Arch Dis Child. 2016. DOI:https://doi.org/10.1136/archdischild-2015-309522
- El-Shaboury AH, Hayes TM. Hyperlipidaemia in asthmatic patients receiving long-term steroid therapy. Br Med J. 1973. DOI:https://doi.org/10.1136/bmj.2.5858.85
- Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004. DOI:https://doi.org/10.7326/0003-4819-141-10-200411160-00007
- Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004. DOI:https://doi.org/10.1136/hrt.2003.020180.
- Lee LN, Bhattacharyya N. Regional and specialty variations in the treatment of chronic rhinosinusitis. Laryngoscope. 2011. DOI:https://doi.org/10.1002/lary.21550
- Hopkins C, Williamson E, Morris S, et al. Antibiotic usage in chronic rhinosinusitis: analysis of national primary care electronic health records. Rhinology. 2019. DOI:https://doi.org/10.4193/Rhin19.136.
- Wallwork B, Coman W, Mackay-Sim A, et al. A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis. Laryngoscope. 2006. DOI:https://doi.org/10.1097/01.mlg.0000191560.53555.08
- Hatipoglu U, Rubinstein I. Treatment of chronic rhinosinusitis with low-dose, long-term macrolide antibiotics: an evolving paradigm. Curr Allergy Asthma Rep. 2005;5(6):491–494.
- Van Zele T, Gevaert P, Watelet JB, et al. Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis [6]. J Allergy Clin Immunol. 2004;114(4):981–983. .
- Head K, Chong LY, Piromchai P, et al. Systemic and topical antibiotics for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016Apr 26:CD0011994
- Tamaoki J, Kadota J, Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med. 2004;117 Suppl 9A:5S–11S.
- Videler WJ, Badia L, Harvey RJ, et al. Lack of efficacy of long-term, low-dose azithromycin in chronic rhinosinusitis: a randomized controlled trial. Allergy Eur J Allergy Clin Immunol. 2011. DOI:https://doi.org/10.1111/j.1398-9995.2011.02693.x.
- Haxel BR, Clemens M, Karaiskaki N, et al. Controlled trial for long-term low-dose erythromycin after sinus surgery for chronic rhinosinusitis. Laryngoscope. 2015;125(5):1048–1055.
- Amali A, Saedi B, Rahavi-Ezabadi S, et al. Long-term postoperative azithromycin in patients with chronic rhinosinusitis: a randomized clinical trial. Am J Rhinol Allergy. 2015. DOI:https://doi.org/10.2500/ajra.2015.29.4244
- Perić A, Baletić N, Milojević M, et al. Effects of preoperative clarithromycin administration in patients with nasal polyposis. West Indian Med J. 2014. DOI:https://doi.org/10.7727/wimj.2013.313.
- Maniakas A, Asmar MH, Renteria AE, et al. Azithromycin in high-risk, refractory chronic rhinosinusitus after endoscopic sinus surgery and corticosteroid irrigations: a double-blind, randomized, placebo-controlled trial. Int Forum Allergy Rhinol. 2020;11: 747-754.
- Cornett E, Novitch MB, Kaye AD, et al. Macrolide and fluoroquinolone mediated cardiac arrhythmias: clinical considerations and comprehensive review. Postgrad Med. 2017;129(7):715–724. .
- Mosholder AD, Lee JY, Zhou EH, et al. Long-Term risk of acute myocardial infarction, stroke, and death with outpatient use of Clarithromycin: a retrospective cohort study. Am J Epidemiol. 2018. DOI:https://doi.org/10.1093/aje/kwx319.
- Winkel P, Hilden J, Hansen JF, et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10 years in the CLARICOR randomised, blinded clinical trial. Int J Cardiol. 2015. DOI:https://doi.org/10.1016/j.ijcard.2015.01.020.
- Andersen SS, Hansen ML, Norgaard ML, et al. Clarithromycin use and risk of death in patients with ischemic heart disease. Cardiology. 2010. DOI:https://doi.org/10.1159/000315394.
- Inghammar M, Nibell O, Pasternak B, et al. Long-Term Risk of Cardiovascular Death with Use of Clarithromycin and Roxithromycin: a Nationwide Cohort Study. Am J Epidemiol. 2018;187(4):777–785.
- Williamson E, Denaxas S, Morris S, et al. Risk of mortality and cardiovascular events following macrolide prescription in chronic rhinosinusitis patients: a cohort study using linked primary care electronic health records. Rhinology 2019. DOI:https://doi.org/10.4193/Rhin18.237
- Wong AYS, Chan EW, Anand S, et al. Managing cardiovascular risk of macrolides: systematic review and Meta-Analysis. Drug Saf. 2017;40(8):663–677. .
- C. C, C. M, A. L, D. M, D HA. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ. 2010;340:c2096
- Pouwels KB, Dolk FCK, Smith DRM, et al. Actual versus “ideal” antibiotic prescribing for common conditions in English primary care. J Antimicrob Chemother. 2018. DOI:https://doi.org/10.1093/jac/dkx502
- Vervloet M, Meulepas MA, Cals JWL, et al. Reducing antibiotic prescriptions for respiratory tract infections in family practice: results of a cluster randomized controlled trial evaluating a multifaceted peer-group-based intervention. Npj Prim Care Respir Med. 2016. DOI:https://doi.org/10.1038/npjpcrm.2015.83
- Van Der Velden AW, Kuyvenhoven MM, Verheij TJM. Improving antibiotic prescribing quality by an intervention embedded in the primary care practice accreditation: the ARTI4 randomized trial. J Antimicrob Chemother. 2016. DOI:https://doi.org/10.1093/jac/dkv328
- Meeker D, Linder JA, Fox CR, et al. Effect of behavioral interventions on inappropriate antibiotic prescribing among primary care practices a randomized clinical trial. J Am Med Assoc. 2016. DOI:https://doi.org/10.1001/jama.2016.0275.
- Shehab N, Patel PR, Srinivasan A, et al. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis. 2008. DOI:https://doi.org/10.1086/591126
- Rothenberg ME, Saito H, Peebles RS. Advances in mechanisms of allergic disease in 2016. J Allergy Clin Immunol. 2017. DOI:https://doi.org/10.1016/j.jaci.2017.08.029
- Tomassen P, Vandeplas G, Van Zele T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016. DOI:https://doi.org/10.1016/j.jaci.2015.12.1324.
- Fort MM, Cheung J, Yen D, et al. IL-25 Induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity. 2001. DOI:https://doi.org/10.1016/S1074-7613(01)00243-6.
- Omori M, Ziegler S. Induction of IL-4 Expression in CD4+T Cells by Thymic Stromal Lymphopoietin. J Immunol. 2007. DOI:https://doi.org/10.4049/jimmunol.178.3.1396
- Chong LY, Piromchai P, Sharp S, et al. Biologics for chronic rhinosinusitis. Cochrane Database Syst Rev. 2020. DOI:https://doi.org/10.1002/14651858.CD013513.pub2
- Lam K, Kern RC, Luong A. Is there a future for biologics in the management of chronic rhinosinusitis? Int Forum Allergy Rhinol. 2016;6(9):935–942.
- Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016. DOI:https://doi.org/10.1016/S0140-6736(16)30307-5.
- Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with Moderate-to-Severe atopic dermatitis. N Engl J Med. 2014. DOI:https://doi.org/10.1056/NEJMoa1314768.
- Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. J Am Med Assoc. 2016. DOI:https://doi.org/10.1001/jama.2015.19330.
- Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019. DOI:https://doi.org/10.1016/S0140-6736(19)31881-1.
- Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis. J Allergy Clin Immunol. 2015;136(6):1431–1440.
- Espinosa ML, Nguyen MT, Aguirre AS, et al. Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients. J Am Acad Dermatol. 2020. DOI:https://doi.org/10.1016/j.jaad.2020.03.050.
- Kouro T, Takatsu K. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol. 2009. DOI:https://doi.org/10.1093/intimm/dxp102
- Huriyati E, Darwin E, Yanwirasti Y, et al. Association of inflammation mediator in mucosal and tissue of chronic rhinosinusitis with recurrent nasal polyp. Open Access Maced J Med Sci. 2019;7:1635-1640
- Stevens WW, Schleimer RP, Kern RC. Chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2016. DOI:https://doi.org/10.1016/j.jaip.2016.04.012
- Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017. DOI:https://doi.org/10.1016/S2213-2600(17)30125-X.
- Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012. DOI:https://doi.org/10.1016/S0140-6736(12)60988-X.
- Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006. DOI:https://doi.org/10.1016/j.jaci.2006.05.031.
- Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011. DOI:https://doi.org/10.1016/j.jaci.2011.07.056.
- Bachert C, Sousa AR, Lund VJ, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol. 2017. DOI:https://doi.org/10.1016/j.jaci.2017.05.044.
- Balzar S, Fajt ML, Comhair SAA, et al. Mast cell phenotype, location, and activation in severe asthma: data from the Severe Asthma Research Program. Am J Respir Crit Care Med. 2011. DOI:https://doi.org/10.1164/rccm.201002-0295OC.
- Hsu Blatman KS, Gonsalves N, Hirano I, et al. Expression of mast cell-associated genes is upregulated in adult eosinophilic esophagitis and responds to steroid or dietary therapy. J Allergy Clin Immunol. 2011. DOI:https://doi.org/10.1016/j.jaci.2010.12.1118
- Bachert C, Zhang N. Chronic rhinosinusitis and asthma: novel understanding of the role of IgE “above atopy.”. J Intern Med. 2012;272(2):133–143.
- Clark DW, Wenaas A, Citardi MJ, et al. Chronic rhinosinusitis with nasal polyps: elevated serum immunoglobulin E is associated with Staphylococcus aureus on culture. Int Forum Allergy Rhinol. 2011. DOI:https://doi.org/10.1002/alr.20079
- Kaplan AP, Giménez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy Eur J Allergy Clin Immunol. 2017;72(4):519–533.
- Beck LA, Marcotte GV, MacGlashan Jr. D, et al. Omalizumab-induced reductions in mast cell FcεRI expression and function. J Allergy Clin Immunol. 2004. DOI:https://doi.org/10.1016/j.jaci.2004.06.032
- Casale TB, Condemi J, LaForce C, et al. Effect of Omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. J Am Med Assoc. 2001. DOI:https://doi.org/10.1001/jama.286.23.2956.
- Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011. DOI:https://doi.org/10.7326/0003-4819-154-9-201105030-00002.
- Pinto JM, Mehta N, DiTineo M, et al. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinol J. 2010. DOI:https://doi.org/10.4193/Rhin09.144
- Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013. DOI:https://doi.org/10.1016/j.jaci.2012.07.047.
- Geveart P, Omachi T, Corren J et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. JACI 2020;146: 595-605.
- Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020. DOI:https://doi.org/10.1016/j.jaci.2020.05.032.
- Hong CJ, Tsang AC, Quinn JG, et al. Anti-IgE monoclonal antibody therapy for the treatment of chronic rhinosinusitis: a systematic review. Syst Rev. 2015;4(1). DOI:https://doi.org/10.1186/s13643-015-0157-5
- Fandinõ M, Macdonald KI, Lee J, et al. The use of postoperative topical corticosteroids in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis. Am J Rhinol Allergy. 2013. DOI:https://doi.org/10.2500/ajra.2013.27.3950
- Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the joint task force on practice parameters in allergy, asthma and immunology. Ann Allergy, Asthma Immunol. 1998;81:478-551
- Leung RM, Dinnie K, Smith TL. When do the risks of repeated courses of corticosteroids exceed the risks of surgery? Int Forum Allergy Rhinol. 2014. DOI:https://doi.org/10.1002/alr.21377
- MacLaughlin EJ, Saseen JJ, Malone DC. Costs of β-lactam allergies: selection and costs of antibiotics for patients with a reported β-lactam allergy. Arch Fam Med. 2000. DOI:https://doi.org/10.1001/archfami.9.8.722